The role of apatinib combined with paclitaxel (aluminum binding type) in platinum-resistant ovarian cancer

OBJECTIVE: To assess the anti-tumor activity and side effects of different dosages of paclitaxel (albumin binding type) (hereinafter referred to as nab-P) combined with Apatinib (hereinafter referred to as AP) in platinum-resistant ovarian cancer cell line and xenograft models. METHODS: SKOV-3/DDP c...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Hong, Li, Rong, Wang, Xiaoyan, Lu, Xin, Hu, Min, Zhang, Jinbin, Zhao, Xia, Song, Xiaoqin, Liu, Yangyang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507263/
https://www.ncbi.nlm.nih.gov/pubmed/32958014
http://dx.doi.org/10.1186/s13048-020-00719-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7507263/
https://www.ncbi.nlm.nih.gov/pubmed/32958014
http://dx.doi.org/10.1186/s13048-020-00719-3

Ejemplares similares